Literature DB >> 9039129

Angiotensin II signaling in vascular smooth muscle. New concepts.

K K Griendling1, M Ushio-Fukai, B Lassègue, R W Alexander.   

Abstract

Angiotensin II is a multifunctional hormone that affects both contraction and growth of vascular smooth muscle cells through a complex series of intracellular signaling events initiated by the interaction of angiotensin II with the AT1 receptor. The cellular response to angiotensin II is multiphasic, involving stimulation within seconds of phospholipase C and Ca2+ mobilization; activation within minutes of phospholipase D, A2, protein kinase C, and MAP kinase; and stimulation after a period of hours of gene transcription and NADH/NADPH oxidase activity. Angiotensin II also activates numerous intracellular tyrosine kinases. In this respect, it shares some aspects of signaling with growth factor and cytokine receptors, including activation of phospholipase C-gamma, src, and ras; association of shc with grb2; and stimulation of the Jak/STAT pathway. The cellular events responsible for this unique series of events may involve receptor movement and the creation of a signaling domain. Elucidation of these pathways is important to our understanding of AT1 receptor function as a final effector of the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039129     DOI: 10.1161/01.hyp.29.1.366

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  70 in total

1.  The role of 3'-untranslated region (3'-UTR) mediated mRNA stability in cardiovascular pathophysiology.

Authors:  C M Misquitta; V R Iyer; E S Werstiuk; A K Grover
Journal:  Mol Cell Biochem       Date:  2001-08       Impact factor: 3.396

2.  The mechanism of the decrease in cytosolic Ca2+ concentrations induced by angiotensin II in the high K(+)-depolarized rabbit femoral artery.

Authors:  M Ushio-Fukai; H Yamamoto; J Nishimura; K Hirano; H Kanaide
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

3.  Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.

Authors:  Derek E Doran; Daiana Weiss; Yong Zhang; Kathy K Griendling; W Robert Taylor
Journal:  Atherosclerosis       Date:  2007-01-16       Impact factor: 5.162

4.  Early endosomal antigen 1 (EEA1) is an obligate scaffold for angiotensin II-induced, PKC-alpha-dependent Akt activation in endosomes.

Authors:  Rafal Robert Nazarewicz; Gloria Salazar; Nikolay Patrushev; Alejandra San Martin; Lula Hilenski; Shiqin Xiong; R Wayne Alexander
Journal:  J Biol Chem       Date:  2010-11-20       Impact factor: 5.157

5.  The frail renin-angiotensin system.

Authors:  Peter M Abadir
Journal:  Clin Geriatr Med       Date:  2011-02       Impact factor: 3.076

6.  Elevated circulating sST2 associated with subclinical atherosclerosis in newly diagnosed primary hypertension.

Authors:  Ihsan Ates; Nihal Ozkayar; Hale Ates; Uğur Nadir Karakulak; Oğuzhan Kursun; Canan Topcuoglu; Bayram Inan; Nisbet Yilmaz
Journal:  Hypertens Res       Date:  2016-02-25       Impact factor: 3.872

7.  A haplotype of angiotensin receptor type 1 associated with human hypertension increases blood pressure in transgenic mice.

Authors:  Sudhir Jain; Alicia Prater; Varunkumar Pandey; Anita Rana; Nitin Puri; Ashok Kumar
Journal:  J Biol Chem       Date:  2013-11-07       Impact factor: 5.157

8.  Vascular smooth muscle cell motility: From migration to invasion.

Authors:  Sherif F Louis; Peter Zahradka
Journal:  Exp Clin Cardiol       Date:  2010

Review 9.  Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance.

Authors:  G H Gibbons
Journal:  Drugs       Date:  1997       Impact factor: 9.546

10.  Baicalein attenuates intimal hyperplasia after rat carotid balloon injury through arresting cell-cycle progression and inhibiting ERK, Akt, and NF-kappaB activity in vascular smooth-muscle cells.

Authors:  Chieh-Yu Peng; Shiow-Lin Pan; Ying-Wen Huang; Jih-Hwa Guh; Ya-Ling Chang; Che-Ming Teng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-29       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.